Comparative Pharmacology
Head-to-head clinical analysis: LIBRITABS versus VALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRITABS versus VALIUM.
LIBRITABS vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment.
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination.
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine